By Adriano Marchese
Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union.
The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor,…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
